NCT03387215View on ClinicalTrials.gov

Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions
Heart Failure, Systolic
Interventions
DRUG

ITI-214

Oral

OTHER

Placebo

Oral

Trial Locations (2)

21287

Johns Hopkins University, Baltimore

27710

Duke Clinical Research Institute, Durham

Sponsors
All Listed Sponsors
lead

Intra-Cellular Therapies, Inc.

INDUSTRY

NCT03387215 - Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure | Biotech Hunter | Biotech Hunter